New study digs deeper into Long-Term benefits of immunotherapy combo for lung cancer

NCT ID NCT07478809

Recruiting now Knowledge-focused Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

First seen Mar 18, 2026 · Last updated May 25, 2026 · Updated 12 times

Summary

This study collects long-term survival data from 109 patients with advanced squamous non-small cell lung cancer who previously received tislelizumab combined with chemotherapy in the RATIONALE-307 trial. The goal is to better understand long-term benefits and identify which patients gain the most from this immunotherapy approach. No new treatments are given; it is a retrospective analysis of existing data.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
RECRUITING

Beijing, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

NSCLC (ADVANCED NON-SMALL CELL LUNG CANCER)